KR20120046216A - 3-시아노퀴놀린 정제 제형 및 이의 용도 - Google Patents

3-시아노퀴놀린 정제 제형 및 이의 용도 Download PDF

Info

Publication number
KR20120046216A
KR20120046216A KR1020127002851A KR20127002851A KR20120046216A KR 20120046216 A KR20120046216 A KR 20120046216A KR 1020127002851 A KR1020127002851 A KR 1020127002851A KR 20127002851 A KR20127002851 A KR 20127002851A KR 20120046216 A KR20120046216 A KR 20120046216A
Authority
KR
South Korea
Prior art keywords
weight
composition
ski
methoxy
microcrystalline cellulose
Prior art date
Application number
KR1020127002851A
Other languages
English (en)
Korean (ko)
Inventor
골디 카울
라마라오 차틀라팔리
아르윈더 나기
크리쉬넨두 고쉬
Original Assignee
와이어쓰 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 와이어쓰 엘엘씨 filed Critical 와이어쓰 엘엘씨
Publication of KR20120046216A publication Critical patent/KR20120046216A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020127002851A 2009-07-02 2010-06-30 3-시아노퀴놀린 정제 제형 및 이의 용도 KR20120046216A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22253709P 2009-07-02 2009-07-02
US61/222,537 2009-07-02

Publications (1)

Publication Number Publication Date
KR20120046216A true KR20120046216A (ko) 2012-05-09

Family

ID=42732381

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127002851A KR20120046216A (ko) 2009-07-02 2010-06-30 3-시아노퀴놀린 정제 제형 및 이의 용도

Country Status (15)

Country Link
EP (1) EP2448563A2 (zh)
JP (1) JP2011012063A (zh)
KR (1) KR20120046216A (zh)
CN (1) CN102470109A (zh)
AR (1) AR077546A1 (zh)
AU (1) AU2010266342A1 (zh)
BR (1) BRPI1015941A2 (zh)
CA (1) CA2766067A1 (zh)
IL (1) IL217298A0 (zh)
MX (1) MX2012000048A (zh)
RU (1) RU2011152105A (zh)
SG (1) SG177309A1 (zh)
TW (1) TW201113050A (zh)
WO (1) WO2011002857A2 (zh)
ZA (1) ZA201200366B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190123764A (ko) 2017-03-31 2019-11-01 닛세이 에이. 에스. 비 기카이 가부시키가이샤 수지제 용기

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101155579B (zh) 2005-02-03 2012-10-31 综合医院公司 治疗吉非替尼耐药性癌症的方法
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR20130088908A (ko) 2008-06-17 2013-08-08 와이어쓰 엘엘씨 Ｈｋｉ-272 및 비노렐빈을 함유하는 항신생물성 조합물
CN109464445A (zh) 2008-08-04 2019-03-15 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
ES2941894T3 (es) 2009-04-06 2023-05-26 Wyeth Llc Régimen de tratamiento que utiliza neratinib contra el cáncer de mama
PT2498756T (pt) 2009-11-09 2019-11-26 Wyeth Llc Formulações de comprimidos de maleato de neratinib
CA2780332C (en) 2009-11-09 2018-01-30 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
CN104447541A (zh) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 博舒替尼化合物
CN105384686B (zh) * 2014-09-04 2019-07-26 连云港润众制药有限公司 一种博舒替尼结晶方法
WO2017175855A1 (en) * 2016-04-08 2017-10-12 Shionogi & Co., Ltd. Stabilized solid dosage form

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
PT1480679E (pt) * 2002-02-26 2007-07-18 Astrazeneca Ab Fórmulação farmacêutica de iressa compreendendo um derivado de celulose solúvel em água
MXPA06001590A (es) 2003-08-19 2006-05-19 Wyeth Corp Proceso para la preparacion de 4-amino-3-quinolincarbonitrilos.
JP4834553B2 (ja) * 2004-09-17 2011-12-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
RU2007148072A (ru) * 2005-07-01 2009-08-10 Вайет (Us) Кристаллические формы 4-[(2,4-дихлор-5-метоксифинил)амино]-6- меокси-7-[3-(4-метил-1-пиперазинил)пропокси]-3-хиналинкарбонитрил и способы их получения
WO2008053295A2 (en) * 2006-10-30 2008-05-08 Wockhardt Research Centre Pharmaceutical compositions of benzoquinolizine-2-carboxylic acid
CN101224185A (zh) * 2007-12-11 2008-07-23 山东蓝金生物工程有限公司 一种治疗实体肿瘤的伯舒替尼缓释植入剂

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190123764A (ko) 2017-03-31 2019-11-01 닛세이 에이. 에스. 비 기카이 가부시키가이샤 수지제 용기

Also Published As

Publication number Publication date
AR077546A1 (es) 2011-09-07
BRPI1015941A2 (pt) 2016-04-19
WO2011002857A2 (en) 2011-01-06
IL217298A0 (en) 2012-02-29
SG177309A1 (en) 2012-02-28
MX2012000048A (es) 2012-01-27
WO2011002857A3 (en) 2011-03-10
CA2766067A1 (en) 2011-01-06
CN102470109A (zh) 2012-05-23
TW201113050A (en) 2011-04-16
AU2010266342A1 (en) 2012-01-19
RU2011152105A (ru) 2013-08-10
JP2011012063A (ja) 2011-01-20
EP2448563A2 (en) 2012-05-09
ZA201200366B (en) 2012-10-31

Similar Documents

Publication Publication Date Title
KR20120046216A (ko) 3-시아노퀴놀린 정제 제형 및 이의 용도
US20210290656A1 (en) Antisense Compositions and Methods of Making and Using Same
EP2498756B1 (en) Tablet formulations of neratinib maleate
JP5775464B2 (ja) 非晶質ｃｄｄｏ−ｍｅを含有する遅延放出性経口投薬組成物
TWI429437B (zh) 經加衣之藥球及彼於除去或減輕徵狀（諸如嘔吐和腹瀉）之用途
TW201206447A (en) Pharmaceutical formulations
TW202313072A (zh) 檸檬酸鐵之兒科調配物
DK177906B1 (en) Dispersible tablet

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application